Martin Krämer Appointed as New CFO at CHEPLAPHARM

On June 1, 2026, CHEPLAPHARM, a leading international pharmaceutical firm based in Greifswald, announced the appointment of Martin Krämer as its new Chief Financial Officer. Krämer joins from Röhm, bringing significant international experience in financial management, corporate governance, and M&A transactions.

Krämer takes over from Dr. Keyarasch Parssanedjad, who moves to a new role as Chief Business & Strategy Officer at CHEPLAPHARM. Krämer's career has involved pivotal roles in strategic and operational finance, notably driving growth and transformation at Röhm.

His responsibilities will span Finance, Internal Audit & Risk Management, and Treasury & Investor Relations. Krämer will report to Co-CEO Sebastian Braun, who praised him as a top-tier finance manager with the capacity to bolster the company's financial strategies during its next growth phase.